Cantor Fitzgerald set a $13.00 target price on Viewray (NASDAQ:VRAY) in a research note released on Monday. The firm currently has a buy rating on the stock.
VRAY has been the topic of several other research reports. ValuEngine cut Viewray from a hold rating to a sell rating in a research report on Friday, December 1st. BidaskClub cut Viewray from a buy rating to a hold rating in a research report on Saturday, December 9th. Mizuho reiterated a buy rating and set a $12.00 target price on shares of Viewray in a research report on Monday, November 13th. Finally, Northland Securities reiterated a buy rating and set a $10.00 target price on shares of Viewray in a research report on Friday, November 17th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $11.20.
Shares of Viewray (VRAY) traded up $0.14 during mid-day trading on Monday, reaching $9.13. The company had a trading volume of 1,390,089 shares, compared to its average volume of 982,233. The firm has a market cap of $639.64, a PE ratio of -8.38 and a beta of 17.60. Viewray has a 1 year low of $3.01 and a 1 year high of $10.39. The company has a debt-to-equity ratio of -1.67, a current ratio of 1.59 and a quick ratio of 1.20.
Viewray (NASDAQ:VRAY) last issued its quarterly earnings results on Monday, November 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.07). The company had revenue of $12.20 million during the quarter, compared to analysts’ expectations of $18.63 million. The business’s revenue was up 2950.0% on a year-over-year basis. equities research analysts predict that Viewray will post -0.93 earnings per share for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Pura Vida Investments LLC increased its position in Viewray by 132.9% during the 3rd quarter. Pura Vida Investments LLC now owns 607,040 shares of the company’s stock worth $3,497,000 after purchasing an additional 346,370 shares during the period. Fosun International Ltd acquired a new position in Viewray during the 3rd quarter worth approximately $640,000. Vanguard Group Inc. increased its position in Viewray by 67.0% during the 2nd quarter. Vanguard Group Inc. now owns 1,026,880 shares of the company’s stock worth $6,644,000 after purchasing an additional 411,866 shares during the period. Schwab Charles Investment Management Inc. acquired a new position in Viewray during the 2nd quarter worth approximately $323,000. Finally, Granite Investment Partners LLC acquired a new position in Viewray during the 3rd quarter worth approximately $492,000. Institutional investors own 50.02% of the company’s stock.
WARNING: “Viewray (VRAY) Given a $13.00 Price Target at Cantor Fitzgerald” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/09/viewray-vray-given-a-13-00-price-target-at-cantor-fitzgerald.html.
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.